ArticleCellular oncology (Dordrecht, Netherlands)2025
SERPINA1 drives TACE resistance in hepatocellular carcinoma by competitively binding ITGB3 to block ITCH-mediated ubiquitination and degradation.
Article in Cellular oncology (Dordrecht, Netherlands), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Post-translational modification in hepatocellular carcinoma resistance: molecular mechanisms and therapeutic targeting.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTransarterial chemoembolization (TACE) is the first-line treatment for intermediate-to-advanced hepatocellular carcinoma (HCC), but post-TACE resistance remains a major clinical challenge. While SERPINA1, a serine protease inhibitor involved in tumor microenvironment regulation, is dysregulated in various cancers, its role in TACE resistance is unclear. This study investigates SERPINA1’s functional and mechanistic involvement in HCC resistance to TACE.
methodsSerum SERPINA1 levels were measured by ELISA in TACE-treated HCC patients. Functional assays under hypoxic/chemotherapeutic conditions and xenograft models assessed tumor progression. Mechanistic studies integrated qRT-PCR, Western blot, co-immunoprecipitation (Co-IP), GST pull-down, molecular docking, and mass spectrometry to elucidate the SERPINA1-ITGB3 interaction.
resultsElevated post-TACE serum SERPINA1 levels were significantly associated with poor treatment response and poor prognosis (P < 0.05). Functional experiments demonstrated that SERPINA1 promoted HCC cell proliferation, migration, and invasion under hypoxic and chemotherapeutic stress, while xenograft models confirmed its tumorigenic role. Mechanistically, SERPINA1 competitively bound to the EGF-like 2/3 domains of ITGB3 via its C-terminal region (amino acids 320–392), thereby shielding ITGB3 from ITCH-mediated polyubiquitination and proteasomal degradation, which consequently sustained oncogenic signaling pathways.
conclusionOur study identifies the SERPINA1-ITGB3 axis as a critical mediator of TACE resistance in HCC, providing a promising therapeutic target to enhance clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.